tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BioInvent and Transgene to Present Promising BT-001 Study Results at ESMO 2025

Story Highlights
  • BioInvent and Transgene will present updated Phase 1 data on BT-001 at ESMO 2025.
  • The study shows promising results for BT-001 in combination with pembrolizumab in treating solid tumors.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
BioInvent and Transgene to Present Promising BT-001 Study Results at ESMO 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from BioInvent International AB ( (SE:BINV) ).

BioInvent International AB and Transgene have announced the presentation of updated data from the Phase 1 part of their ongoing Phase 1/2a study of the oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The study, which involves using BT-001 in combination with pembrolizumab, has shown promising results, with clinical responses observed in some patients with advanced solid tumors. This development could enhance BioInvent’s position in the cancer immunotherapy market and provide new treatment options for patients with refractory tumors.

More about BioInvent International AB

BioInvent International AB is a biotechnology company specializing in the discovery and development of novel antibodies for cancer immunotherapy. The company focuses on creating first-in-class immune-modulatory therapies. Transgene, its collaborator, is a biotechnology company that designs and develops virus-based immunotherapies for cancer treatment, with a portfolio that includes viral immunotherapeutics and oncolytic viruses.

Average Trading Volume: 101,240

Technical Sentiment Signal: Buy

Current Market Cap: SEK2.7B

For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1